公开(公告)号：US20210322418A1

公开(公告)日：2021-10-21

申请号：US17258894

申请日：2019-07-15

申请人： |NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE PARIS ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

发明人： Daniel ABERDAM ,  Edith ABERDAM ,  Smail HADJ-RABIA ,  Salvatore CISTERNINO

IPC分类号： A61K31/517 ,  A61K31/439 ,  A61P17/02

摘要： The present invention relates to a method for promoting wound healing in a subject suffering from Ectodermal dysplasia in need thereof comprising a step of administering subcutaneously, intradermally or topically to said subject a therapeutically effective amount of a compound which restores the activity of p63. Inventors have performed a primary culture of patient keratinocytes suffering from ectodermal dysplasias with two compounds which restore the activity of p63 (e.g. STIMA-1 and/or PRIMA-1Met). They have shown that there is an important differentiation of the keratinocytes of said patient compared to the cells not treated with these compounds. They observed that the activity of p63 mutated is restored, thus the proliferation and differentiation of keratinocytes from the patient are activated. Moreover, inventors have used PRIMA-1Met by topical application on a young patient suffering from ectodermal dysplasias and shown that said patient presents an improvement on her hand. Typically, severe skin erosions (on hands and feet) are healing when PRIMA-1Met is administered topically on the hand.

公开(公告)号：US20220117911A1

公开(公告)日：2022-04-21

申请号：US17428396

申请日：2020-02-03

申请人： INSERM (institut National de la Santé et de la Recherche Médicale) ,  Université de Paris ,  Assistance Publique-Hôpitaux de Paris (APHP)

发明人： Xavier DECLEVES ,  Salvatore CISTERNINO ,  Bruno SAUBAMEA ,  Huilong LUO

IPC分类号： A61K31/05 ,  A61K45/06

摘要： The present invention relates to a method for modulating blood-brain barrier (BBB) in a subject comprising a step of administering said subject with a therapeutically effective amount of a modulator of transient receptor potential vanilloid-2 (TRPV2). For the first time, inventors have shown that TRPV2 is present in endothelial cells of BBB. More particularly, Inventor's results show that cannabidiol (CBD), at extracellular concentrations close to those observed in plasma of patients treated by CBD, and induces proliferation, migration, tubulogenesis and TEER increase in human brain endothelial cells, suggesting TRPV2 as a potent target for modulating the human BBB.

公开(公告)号：US20230149405A1

公开(公告)日：2023-05-18

申请号：US17916904

申请日：2021-04-07

申请人： LABORATOIRES C.T.R.S. ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  FONDATION IMAGINE ,  UNIVERSITÉ PARIS CITÉ ,  UNIVERSITE PARIS-SACLAY

发明人： Christine BODEMER ,  Céline GRECO ,  Claude BOUCHEIX ,  Jean-Pascal CONDUZORGUES ,  Joel SCHLATTER ,  Salvatore CISTERNINO

IPC分类号： A61K31/517 ,  A61K9/00 ,  A61K9/107 ,  A61K9/08 ,  A61P17/02 ,  A61K47/10 ,  A61K47/40 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K31/517 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/08 ,  A61P17/02 ,  A61K47/10 ,  A61K47/40 ,  A61K47/32 ,  A61K47/38

摘要： A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.